Mon panier

Fas

Fas Informations sur la molécule

Nom anglaisApoptosis-mediating surface antigen FASNombre de médicaments commercialisés1
Nombre de médicaments cliniques1Alias de la cibleTumor Necrosis Factor Receptor Superfamily, Member 6,Apo-1 antigen,CD95,APT1,FAS1,TNFRSF6,FAS,Fas Cell Surface Death Receptor,Fas (TNF Receptor Superfamily, Member 6),Apoptosis-Mediating Surface Antigen FAS,TNF Receptor Superfamily Member 6,FASLG Receptor,CD95 Antigen,Mutant Tumor Necrosis Receptor Superfamily Member 6,Tumor Necrosis Factor Receptor Superfamily Member 6,Apoptosis Signaling Receptor FAS,APO-1 Cell Surface Antigen,Apoptosis Antigen 1,Fas AMA,ALPS1A,APO-1,FASTM,fas Receptor
Phase de R&D la plus avancéeApproved
Nom anglaisApoptosis-mediating surface antigen FAS
Alias de la cibleTumor Necrosis Factor Receptor Superfamily, Member 6,Apo-1 antigen,CD95,APT1,FAS1,TNFRSF6,FAS,Fas Cell Surface Death Receptor,Fas (TNF Receptor Superfamily, Member 6),Apoptosis-Mediating Surface Antigen FAS,TNF Receptor Superfamily Member 6,FASLG Receptor,CD95 Antigen,Mutant Tumor Necrosis Receptor Superfamily Member 6,Tumor Necrosis Factor Receptor Superfamily Member 6,Apoptosis Signaling Receptor FAS,APO-1 Cell Surface Antigen,Apoptosis Antigen 1,Fas AMA,ALPS1A,APO-1,FASTM,fas Receptor
Nombre de médicaments commercialisés1
Nombre de médicaments cliniques1
Phase de R&D la plus avancéeApproved

Fas Liste de produits

  • Attribut

    Protein (2)

  • Bibliothèque de produits

    En ligne (2)

  • Espèces

    Human (2)

  • Étiquette

    Fc Tag (1)His Tag (1)

  • Marqueur

    Unconjugated (2)

Numéro de produitEspècesSystème d'expressionDescription du produitStructure protéiquePuretéCaractéristiquesPré-commande/Commande
FAS-H5229
Human
HEK293
Human Fas / TNFRSF6 / CD95 Protein, His Tag (MALS verified)
Ajouter au panier
FAS-H5252
Human
HEK293
Human Fas / TNFRSF6 / CD95 Protein, Fc Tag (MALS verified)
Ajouter au panier
Quantité totale2
  • 1

FasContexte de la molécule

The Fas is also known as FAS receptor (FasR), apoptosis antigen 1 (APO-1 or APT), cluster of differentiation 95 (CD95) or tumor necrosis factor receptor superfamily member 6 (TNFRSF6). is a death receptor on the surface of cells that leads to programmed cell death (apoptosis). It is one of two apoptosis pathways, the other being the mitochondrial pathway. FasR is located on chromosome 10 in humans and 19 in mice. Similar sequences related by evolution (orthologs) are found in most mammals. Fas forms the death-inducing signaling complex (DISC) upon ligand binding. Membrane-anchored Fas ligand trimer on the surface of an adjacent cell causes trimerization of Fas receptor. This event is also mimicked by binding of an agonistic Fas antibody, though some evidence suggests that the apoptotic signal induced by the antibody is unreliable in the study of Fas signaling. To this end, several clever ways of trimerizing the antibody for in vitro research have been employed.Upon ensuing death domain (DD) aggregation, the receptor complex is internalized via the cellular endosomal machinery. This allows the adaptor molecule FADD to bind the death domain of Fas through its own death domain. Recently, Fas has also been shown to promote tumor growth, since during tumor progression, it is frequently downregulated or cells are rendered apoptosis resistant. Cancer cells in general, regardless of their Fas apoptosis sensitivity, depend on constitutive activity of Fas. This is stimulated by cancer-produced Fas ligand for optimal growth.

FasAlias de la molécule

FAS,ALPS1A,APO1,APT1,CD95,FAS1,FASTM,TNFRSF6,FasR

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
XelafaslatideONL-1204Phase 2 ClinicalOnl TherapeuticsGeographic Atrophy; Glaucoma, Open-Angle; Macular Degeneration; Retinal Detachment
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
KanglaiteApprovedZhejiang Kanglaite Pharmaceutical Co LtdKanglaiteMainland ChinaLiver Neoplasms; Carcinoma, Non-Small-Cell LungZhejiang Kanglaite Pharmaceutical Co Ltd1997-01-01Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours
Details

Avis sur les produits

  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Avis sur les produits
  • Informations sur les médicaments cliniques